



204240" 856T400T



INDIVIDUAL Stx2-  
SPECIFIC Hu-mAb  
BINDING PATTERNS

FIG.1

SUMMARY OF Stx2 Hu mAb ACTIVITY  
AGAINST CLINICAL Stx2 AND Stx2 VARIANTS




FIG.2




FIG.3

AVERAGE SURVIVAL OF MICE GIVEN 5,10,20,35 OR 50  $\mu$ g  
OF Stx2-SPECIFIC Hu-mAbs FOLLOWED 18 HOURS LATER  
WITH 25ng Stx2





FIG.4


IN VITRO NEUTRALIZATION OF Stx2 AND Stx2c  
(PRODUCED BY CLINICAL STEC ISOLATES)  
BY Stx2-SPECIFIC Hu-mAb



5H8=anti-A+B subunit  
6G3=anti-A+B subunit  
2F10=anti-A subunit  
3E9=anti-A subunit  
5C12=anti-A subunit

FIG.5

AVERAGE DAYS OF SURVIVAL OF MICE GIVEN 30 $\mu$ g  
Hu-m Ab 2F10, 3E9, 5C12, 5H8, OR 6G3 FOLLOWED 18 HOURS LATER  
WITH Stx2c CONTAINING CULTURE SUPERNATANT



Stx2c PRODUCING E.coli ISOLATE (95-8061)

FIG.6